Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James Chih‐Hsin Yang(National Taiwan University Hospital), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Nobuyuki Yamamoto(Wakayama Medical University), Martin Schüler(German Cancer Research Center), Sarayut Lucien Geater(Prince of Songkla University), Tony Mok(Chinese University of Hong Kong), Victoria Zazulina(Taipei Veterans General Hospital), Lecia V. Sequist(Harvard University), Daniel Massey(Boehringer Ingelheim (United Kingdom)), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Caicun Zhou(Tongji University), Chun-Ming Tsai(Taipei Veterans General Hospital), Chong‐Jen Yu(National Taiwan University Hospital)
Cited by 980
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k